Navigation Links
Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
Date:4/8/2008

SAN DIEGO, April 8, 2008 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it initiated screening in a Phase 2b clinical trial of APD125 in patients with primary insomnia. APD125 is an oral drug candidate discovered by Arena with the potential to reduce insomnia symptoms and improve sleep maintenance and quality.

The Phase 2b trial of APD125 is a double-blind, randomized, placebo- controlled subjective study evaluating the efficacy and tolerability of APD125 in patients with primary insomnia characterized by difficulty maintaining sleep. The trial, which is expected to enroll a total of approximately 675 male and female patients in about 70 clinical sites in the United States, will evaluate two doses (20 mg and 40 mg) and placebo over 14 nights of treatment. The trial will evaluate standard subjective measurements of sleep, including change from baseline in subjective number of awakenings after sleep onset (sNAASO), which is the primary endpoint.

"We are very encouraged by the emerging profile of APD125. We believe APD125 has the potential to significantly improve sleep maintenance and quality for patients with insomnia without the potential for dependence or impairing psychomotor function," said Jack Lief, Arena's President and Chief Executive Officer. "Results from this trial are expected around year end, and we believe they will increase our understanding of APD125 while supporting ongoing partnership efforts."

In a Phase 2a trial, when compared to placebo, patients treated with APD125 achieved statistically significant improvements in objective measurements of sleep maintenance, or the ability to maintain sleep during the night after falling asleep, and sleep architecture. T
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2015   Physicians Rx Pharmacy ("PRxP") today ... the organization as President and Chief Executive Officer.  ... and Chief Executive Officer for Soleo Health Specialty Infusion ... Physicians Rx Pharmacy, be responsible for leading the rapidly-growing ... pleased to bring Gaston on as the President and ...
(Date:9/2/2015)... Calif. , Sept. 2, 2015 ... submission of a Marketing Authorization Application (MAA) to ... procedure for etelcalcetide (formerly AMG 416) for the ... with chronic kidney disease (CKD) on hemodialysis therapy. ... agent that can be administered intravenously. ...
(Date:9/2/2015)... 2015  Seeger Weiss LLP is reporting that Zimmer ... October 13, 2015. Since the product ... program, Zimmer NexGen knee implant surpassed FDA investigation and ... provide evidence that the product is substantially similar to ... permissions. In 2001, Zimmer began distributing ...
Breaking Medicine Technology:Gaston L. Bernstein Named President and CEO of Physicians Rx Pharmacy 2Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 2Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 3Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 4Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 5Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 6Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 7Seeger Weiss LLP Reports That Zimmer NexGen Knee MDL Bellwether Trial Date Set For October 13, 2015 2
... Calif., Jan. 3, 2012  Cutera, Inc. (NASDAQ: ... ) today announced that the companies have entered into ... of IRIDEX, global aesthetic business for approximately $5.1 million. ... $1 billion global aesthetic market, with IRIDEX, strength in ...
... 3, 2012 Reportlinker.com announces that ... available in its catalogue: ... (PE/VC) Activity in Medical Devices - ... has Increased over the Past Four ...
Cached Medicine Technology:Cutera and IRIDEX Announce Acquisition of IRIDEX' Aesthetic Business Unit 2Cutera and IRIDEX Announce Acquisition of IRIDEX' Aesthetic Business Unit 3Cutera and IRIDEX Announce Acquisition of IRIDEX' Aesthetic Business Unit 4Private Equity and Venture Capital (PE/VC) Activity in Medical Devices - Number of Investments in Smaller Companies has Increased over the Past Four Years 2Private Equity and Venture Capital (PE/VC) Activity in Medical Devices - Number of Investments in Smaller Companies has Increased over the Past Four Years 3Private Equity and Venture Capital (PE/VC) Activity in Medical Devices - Number of Investments in Smaller Companies has Increased over the Past Four Years 4Private Equity and Venture Capital (PE/VC) Activity in Medical Devices - Number of Investments in Smaller Companies has Increased over the Past Four Years 5Private Equity and Venture Capital (PE/VC) Activity in Medical Devices - Number of Investments in Smaller Companies has Increased over the Past Four Years 6Private Equity and Venture Capital (PE/VC) Activity in Medical Devices - Number of Investments in Smaller Companies has Increased over the Past Four Years 7Private Equity and Venture Capital (PE/VC) Activity in Medical Devices - Number of Investments in Smaller Companies has Increased over the Past Four Years 8Private Equity and Venture Capital (PE/VC) Activity in Medical Devices - Number of Investments in Smaller Companies has Increased over the Past Four Years 9Private Equity and Venture Capital (PE/VC) Activity in Medical Devices - Number of Investments in Smaller Companies has Increased over the Past Four Years 10Private Equity and Venture Capital (PE/VC) Activity in Medical Devices - Number of Investments in Smaller Companies has Increased over the Past Four Years 11
(Date:9/3/2015)... ... 2015 , ... Global Vision , the world leader in the development ... print and artwork inspection solutions, ScanProof and ArtProof at Packaging Innovations 2015. ... London, booth #F33 , Be the first to get a sneak peek of Intelligent ...
(Date:9/3/2015)... Philadelphia (PRWEB) , ... September ... ... global provider of high-quality patient safety and efficacy endpoint data collection, cloud ... Annual European PRO and eCOA Congress in Lisbon, Portugal, September 22-24, 2015. ...
(Date:9/3/2015)... ... ... “Love in Tokyo” an independent romantic comedy film by Michael Solton was ... will be released on DVD early next year, by Maverick Entertainment. The film stars ... singer/songwriter, and Jason London, lead from “Dazed and Confused.” , “Love in Tokyo” ...
(Date:9/3/2015)... ... , ... When looking at the types of people who have a hard time gaining ... have a weak appetite or those that have a fast metabolism. In order to help ... Gainer gives three tips for slowing down metabolism. , The first thing to do is ...
(Date:9/3/2015)... ... 2015 , ... Doctor Kayode Sotonwa can be counted on time ... on internal medicine keeps patients happy and healthy, something that is important to everyone. ... season, but even more so in the fall, when holiday eating and seasonal illnesses ...
Breaking Medicine News(10 mins):Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 2Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 3Health News:ERT Announces Final Agenda, Faculty for European PRO / eCOA Congress 2Health News:ERT Announces Final Agenda, Faculty for European PRO / eCOA Congress 3Health News:The Romantic Comedy Film "Love in Tokyo" Has Been Released on ITunes, Google Play, and Amazon 2Health News:CB-1 Weight Gainer Gives Three Tips for Slowing Down Metabolism 2Health News:CB-1 Weight Gainer Gives Three Tips for Slowing Down Metabolism 3Health News:Doctor Kayode Sotonwa Highlights Expert Tips for Staying in Shape This Fall 2
... ... by YHC magazine on April 25. , ... (Vocus) April 10, 2010 -- The Khanna institute to attend the YHC Health ... Village, CA 91361, , , , ,Khanna Institute of LASIK & Refractive surgery, an eye ...
... and non-sensitive folks process input differently , SATURDAY, ... the world around them in a different way, introverted ... stimuli than other people, according to a new study. ... an inborn trait that can be seen in children ...
... ... new website that highlights the practice’s state-of-the-art treatments and gentle, personalized approach. Drs. Bradley A. ... engaging look at all the practice has to offer. , ... San Diego, CA (Vocus) April 10, 2010 -- Two ...
... ... trainers in the state, Dr. Jeffrey Raval has pioneered a new process to make the ... injectable fillers, a practice that the FDA approved in 2009. , ... Denver, Colo. (PRWEB) April 10, 2010 -- As an ...
... ... , ... April 9, 2010 -- Three months on from one of the worst disasters ever witnessed, ... , , ,The international disaster relief charity has now delivered over 13,000 ShelterBoxes to ...
... ... presented by psychologist Paul G. Swingle, illustrates the use of neurotherapy in treating patients ... ADD, ADHD, epilepsy, stroke, learning disorders, traumatic brain injury, depression, fibromyalgia, and autistic spectrum ... ...
Cached Medicine News:Health News:Khanna Institute of Vision and Your Health Connection Spring Expo 2Health News:Khanna Institute of Vision and Your Health Connection Spring Expo 3Health News:Shyness May Be Rooted in Brain Processing 2Health News:San Diego Cosmetic Dentists Launch New Website and Rejuvenate Online Image 2Health News:San Diego Cosmetic Dentists Launch New Website and Rejuvenate Online Image 3Health News:Dr. Jeffrey Raval Pioneers New Method for Filler Facelifts 2Health News:Dr. Jeffrey Raval Pioneers New Method for Filler Facelifts 3Health News:Thousands More ShelterBoxes to be Sent to Haiti 2Health News:Thousands More ShelterBoxes to be Sent to Haiti 3Health News:Psychologist and Author Paul G. Swingle Talks about his Approach to Treating Depression and Mood Disorders in Online Forum 2Health News:Psychologist and Author Paul G. Swingle Talks about his Approach to Treating Depression and Mood Disorders in Online Forum 3
Look to the intuitive iLab System to deliver the best IVUS image quickly and easily. This easy-to-use installed system with tableside controller is the Clear Choice for IVUS....
... full picture ,CardioPAL SAVI is the ... cial Intelligence, with a smart algorithm running ... on each device. The Diogenes algorithm continuously ... rate, rhythm, morphology, and p-wave abnormalities ...
A patient care system tailored to your specific needs that supports current and previous-generation ICDs and pacemakers....
The Rio Catheter is designed to simplify your intravascular interventions by removing thrombus and restoring epicardial flow to the procedure....
Medicine Products: